IgE+ PLASMABLASTS AS A PREDICTIVE BIOMARKER OF ALLERGY
AssigneeCornell University
InventorsBettina WAGNER, Elisabeth SIMONIN, Susanna BABASYAN
Life of this patent
Estimating the term…
Abstract
Methods of detecting IgE+ plasmablasts in a mammal are described herein. Also described herein are methods of predicting clinical allergy in a mammal. Additionally, methods of monitoring progression of an allergy along with methods of monitoring efficacy of treatment of an allergy are described.
Claims40
A method of detecting IgE+ plasmablasts in a mammal, comprising:
- (i) contacting peripheral blood leukocytes (PBL) or peripheral blood mononuclear cells (PBMC) isolated from a blood sample of the mammal, with an acidic wash solution, and thereafter collecting the cells;
- (ii) contacting the collected cells from step (i) with a detection agent directed to IgE;
- and
- (iii) detecting IgE+ cells as IgE+ plasmablasts.
A method of quantifying IgE, comprising
- culturing peripheral blood leukocytes (PBLs) or peripheral blood mononuclear cells (PBMCs) isolated from a blood sample of the mammal,
- measuring IgE secreted from the cultured cells in the supernatant;
- and
- quantifying the level of secreted IgE.
A method of predicting clinical allergy in a mammal, comprising
- detecting IgE+ plasmablasts in the mammal or detecting secreted IgE from cultured PBLs or PMBCs of the mammal, and
- determining the risk of developing clinical allergy based on the level of IgE+ plasmablasts or the level of secreted IgE.
A method of determining the severity of clinical allergy in a mammal, comprising
- detecting IgE+ plasmablasts in the mammal or detecting secreted IgE from cultured PBLs or PMBCs of the mammal, and
- determining the severity of clinical allergy based on the level of IgE+ plasmablasts or the level of secreted IgE.
A method for monitoring progression of an allergy comprising:
- monitoring the level of IgE+ plasmablasts in a mammal or the level of secreted IgE from cultured PBLs or PMBCs of the mammal, and
- determining that allergy is progressing based on an increase in the level of IgE+ plasmablasts or the level of secreted IgE.
A method for monitoring the efficacy of a treatment regimen for allergy, comprising:
- monitoring the level of IgE+ plasmablasts in a mammal or the level of secreted IgE from cultured PBLs or PMBCs of the mammal, wherein the mammal is undergoing the treatment regimen for allergy, and
- determining the efficacy of the treatment regimen based on the level of IgE+ plasmablasts or the level of secreted IgE, wherein a decrease in the level of IgE+ plasmablasts or the level of secreted IgE indicates that the treatment regimen is effective.
The method according to any one of 26-28, wherein the level of IgE+ plasmablasts is determined based on the percentage of CD23+ and IgE+ cells in the total CD23+ cells;
- or
- wherein the level of IgE+ plasmablasts is determined based on the percentage of IgE+ cells in the total cells.
A kit for detecting IgE+ plasmablasts, comprising an acidic wash solution and a monoclonal anti-IgE antibody.
Dependencies are inferred from the claim text.